首页> 外文期刊>Journal of cellular biochemistry. >Involvement of ALAD-20S Proteasome Complexes in Ubiquitination and Acetylation of Proteasomal alpha 2 Subunits
【24h】

Involvement of ALAD-20S Proteasome Complexes in Ubiquitination and Acetylation of Proteasomal alpha 2 Subunits

机译:ALAD-20S蛋白酶体复合体参与泛素化和蛋白酶体α2亚基的乙酰化。

获取原文
获取原文并翻译 | 示例
           

摘要

The ubiquitin-proteasome pathway has gained attention as a potential chemotherapeutic target, owing to its importance in the maintenance of protein homeostasis and the observation that cancer cells are more dependent on this pathway than normal cells. Additionally, inhibition of histone deacetylases (HDACs) by their inhibitors like Vorinostat (SAHA) has also proven a useful strategy in cancer therapy and the concomitant use of proteasome and HDAC inhibitors has been shown to be superior to either treatment alone. It has also been reported that delta-aminolevulinic acid dehydratase (ALAD) is a proteasome-associated protein, and may function as an endogenous proteasome inhibitor. While the role of ALAD in the heme biosynthetic pathway is well characterized, little is known about its interaction with, and the mechanism by which it inhibits, the proteasome. In the present study, this ALAD-proteasome complex was further characterized in cultured prostate cancer cells and the effects of SAHA treatment on the regulation of ALAD were investigated. ALAD interacts with the 20S proteasomal core, but not the 19S regulatory cap. Some ubiquitinated species were detected in ALAD immunoprecipitates that have similar molecular weights to ubiquitinated proteasomal alpha 2 subunits, suggesting preferred binding of ALAD to ubiquitinated a2. Additionally, SAHA treatment increases levels of ALAD protein and an acetylated protein with a molecular weight similar to the ubiquitinated a2 subunit. Thus, the results of this study suggest that ALAD may play a regulatory role in a previously unreported post-translational modification of proteasomal a subunits. (C) 2015 Wiley Periodicals, Inc.
机译:泛素-蛋白酶体途径作为潜在的化学治疗靶点已受到关注,这是由于其在维持蛋白质稳态方面的重要性,以及观察到癌细胞比正常细胞更依赖于这种途径的观点。另外,已证明通过其抑制剂如伏立诺他抑制剂(SAHA)抑制组蛋白脱乙酰基酶(HDACs)在癌症治疗中是一种有用的策略,并且蛋白酶体和HDAC抑制剂的同时使用已证明优于单独使用任何一种治疗方法。还已经报道,δ-氨基乙酰丙酸脱水酶(ALAD)是与蛋白酶体相关的蛋白质,并且可以用作内源性蛋白酶体抑制剂。虽然ALAD在血红素生物合成途径中的作用已得到很好的表征,但对其与蛋白酶体的相互作用以及其抑制蛋白酶体的机制知之甚少。在本研究中,在培养的前列腺癌细胞中进一步表征了这种ALAD-蛋白酶体复合物,并研究了SAHA处理对ALAD调节的影响。 ALAD与20S蛋白酶体核心相互作用,但不与19S监管上限相互作用。在ALAD免疫沉淀物中检测到一些泛素化的物种,其分子量与泛素化的蛋白酶体α2亚基的分子量相似,表明ALAD与泛素化的a2的优先结合。另外,SAHA治疗增加了ALAD蛋白和乙酰化蛋白的水平,其分子量类似于泛素化的α2亚基。因此,这项研究的结果表明,ALAD可能在蛋白酶体a亚基以前未报道的翻译后修饰中起调节作用。 (C)2015威利期刊公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号